Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Corrigendum to "Alzheimer's Disease Dementia as the Diagnosis Best Supported by the Cerebrospinal Fluid Biomarkers: Difference in Cut-Off Levels from Thai Experience".

International journal of Alzheimer's disease

Senanarong V, Sivasariyanonda N, Wachirutmanggur L, Poungvarin N, Rattanabannakit C, Aoonkaew N, Udompunthurak S.
PMID: 28469949
Int J Alzheimers Dis. 2017;2017:2647086. doi: 10.1155/2017/2647086. Epub 2017 Apr 02.

[This corrects the article DOI: 10.1155/2012/212063.].

Cite
Senanarong V, Sivasariyanonda N, Wachirutmanggur L, et al. Corrigendum to "Alzheimer's Disease Dementia as the Diagnosis Best Supported by the Cerebrospinal Fluid Biomarkers: Difference in Cut-Off Levels from Thai Experience". Int J Alzheimers Dis. 2017;2017:2647086doi: 10.1155/2017/2647086.
Senanarong, V., Sivasariyanonda, N., Wachirutmanggur, L., Poungvarin, N., Rattanabannakit, C., Aoonkaew, N., & Udompunthurak, S. (2017). Corrigendum to "Alzheimer's Disease Dementia as the Diagnosis Best Supported by the Cerebrospinal Fluid Biomarkers: Difference in Cut-Off Levels from Thai Experience". International journal of Alzheimer's disease, 20172647086. https://doi.org/10.1155/2017/2647086
Senanarong, Vorapun, et al. "Corrigendum to "Alzheimer's Disease Dementia as the Diagnosis Best Supported by the Cerebrospinal Fluid Biomarkers: Difference in Cut-Off Levels from Thai Experience"." International journal of Alzheimer's disease vol. 2017 (2017): 2647086. doi: https://doi.org/10.1155/2017/2647086
Senanarong V, Sivasariyanonda N, Wachirutmanggur L, Poungvarin N, Rattanabannakit C, Aoonkaew N, Udompunthurak S. Corrigendum to "Alzheimer's Disease Dementia as the Diagnosis Best Supported by the Cerebrospinal Fluid Biomarkers: Difference in Cut-Off Levels from Thai Experience". Int J Alzheimers Dis. 2017;2017:2647086. doi: 10.1155/2017/2647086. Epub 2017 Apr 02. PMID: 28469949; PMCID: PMC5392390.
Copy Download .nbib Format: NLM
The roles of p53 and XPO1 on colorectal cancer progression in Yemeni patients.

Journal of gastrointestinal oncology

Aladhraei M, Al-Salami E, Poungvarin N, Suwannalert P.
PMID: 31183193
J Gastrointest Oncol. 2019 Jun;10(3):437-444. doi: 10.21037/jgo.2019.01.17.

BACKGROUND: The colorectal cancer (CRC) tumorigenesis is driving by genetic alterations leading to changes in protein expression such as p53. The p53 is frequently expressed in CRC and its association with clinicopathological features is still controversial. Moreover, accumulated evidence...

Cite
Aladhraei M, Al-Salami E, Poungvarin N, et al. The roles of p53 and XPO1 on colorectal cancer progression in Yemeni patients. J Gastrointest Oncol. 2019;10(3):437-444doi: 10.21037/jgo.2019.01.17.
Aladhraei, M., Al-Salami, E., Poungvarin, N., & Suwannalert, P. (2019). The roles of p53 and XPO1 on colorectal cancer progression in Yemeni patients. Journal of gastrointestinal oncology, 10(3), 437-444. https://doi.org/10.21037/jgo.2019.01.17
Aladhraei, Mohammed, et al. "The roles of p53 and XPO1 on colorectal cancer progression in Yemeni patients." Journal of gastrointestinal oncology vol. 10,3 (2019): 437-444. doi: https://doi.org/10.21037/jgo.2019.01.17
Aladhraei M, Al-Salami E, Poungvarin N, Suwannalert P. The roles of p53 and XPO1 on colorectal cancer progression in Yemeni patients. J Gastrointest Oncol. 2019 Jun;10(3):437-444. doi: 10.21037/jgo.2019.01.17. PMID: 31183193; PMCID: PMC6534720.
Copy Download .nbib Format: NLM
Placebo-controlled double-blind cross-over study of botulinum A toxin in hemifacial spasm.

Parkinsonism & related disorders

Poungvarin N, Viriyavejakul A, Komoltri C.
PMID: 18591006
Parkinsonism Relat Disord. 1995 Oct;1(2):85-8. doi: 10.1016/1353-8020(95)00003-8.

The evaluation of the efficacy of botulinum A toxin injection for hemifacial spasm has never previously been done in a double-blind study in spite of its use as a treatment. We thus conducted a double-blind cross-over study of botulinum...

Cite
Poungvarin N, Viriyavejakul A, Komoltri C. Placebo-controlled double-blind cross-over study of botulinum A toxin in hemifacial spasm. Parkinsonism Relat Disord. 1995;1(2):85-8doi: 10.1016/1353-8020(95)00003-8.
Poungvarin, N., Viriyavejakul, A., & Komoltri, C. (1995). Placebo-controlled double-blind cross-over study of botulinum A toxin in hemifacial spasm. Parkinsonism & related disorders, 1(2), 85-8. https://doi.org/10.1016/1353-8020(95)00003-8
Poungvarin, N, et al. "Placebo-controlled double-blind cross-over study of botulinum A toxin in hemifacial spasm." Parkinsonism & related disorders vol. 1,2 (1995): 85-8. doi: https://doi.org/10.1016/1353-8020(95)00003-8
Poungvarin N, Viriyavejakul A, Komoltri C. Placebo-controlled double-blind cross-over study of botulinum A toxin in hemifacial spasm. Parkinsonism Relat Disord. 1995 Oct;1(2):85-8. doi: 10.1016/1353-8020(95)00003-8. PMID: 18591006.
Copy Download .nbib Format: NLM
Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines.

Oncology reports

Thongchot S, Jamjuntra P, Prasopsiri J, Thuwajit P, Sawasdee N, Poungvarin N, Warnnissorn M, Sa-Nguanraksa D, O-Charoenrat P, Yenchitsomanus PT, Thuwajit C.
PMID: 34651665
Oncol Rep. 2021 Dec;46(6). doi: 10.3892/or.2021.8205. Epub 2021 Oct 15.

Breast cancer cell lines are widely used as an

Cite
Thongchot S, Jamjuntra P, Prasopsiri J, et al. Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines. Oncol Rep. 2021;46(6)doi: 10.3892/or.2021.8205.
Thongchot, S., Jamjuntra, P., Prasopsiri, J., Thuwajit, P., Sawasdee, N., Poungvarin, N., Warnnissorn, M., Sa-Nguanraksa, D., O-Charoenrat, P., Yenchitsomanus, P. T., & Thuwajit, C. (2021). Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines. Oncology reports, 46(6), . https://doi.org/10.3892/or.2021.8205
Thongchot, Suyanee, et al. "Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines." Oncology reports vol. 46,6 (2021). doi: https://doi.org/10.3892/or.2021.8205
Thongchot S, Jamjuntra P, Prasopsiri J, Thuwajit P, Sawasdee N, Poungvarin N, Warnnissorn M, Sa-Nguanraksa D, O-Charoenrat P, Yenchitsomanus PT, Thuwajit C. Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines. Oncol Rep. 2021 Dec;46(6). doi: 10.3892/or.2021.8205. Epub 2021 Oct 15. PMID: 34651665; PMCID: PMC8548790.
Copy Download .nbib Format: NLM
BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma.

OncoTargets and therapy

Pongsapich W, Chongkolwatana C, Poungvarin N, Amornpichetkul K, Piyawattayakorn N, Vejvisithsakul P, Maneeprasopchoke P.
PMID: 30863114
Onco Targets Ther. 2019 Feb 21;12:1465-1473. doi: 10.2147/OTT.S190001. eCollection 2019.

PURPOSE: Fine-needle aspiration biopsy (FNAB) is regarded by the Bethesda system as the gold-standard investigation for stratifying the risk of malignancy of a thyroid nodule. However, some limitations affect the adequacy of the obtained materials, resulting in 30% of...

Cite
Pongsapich W, Chongkolwatana C, Poungvarin N, et al. BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma. Onco Targets Ther. 2019;12:1465-1473doi: 10.2147/OTT.S190001.
Pongsapich, W., Chongkolwatana, C., Poungvarin, N., Amornpichetkul, K., Piyawattayakorn, N., Vejvisithsakul, P., & Maneeprasopchoke, P. (2019). BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma. OncoTargets and therapy, 121465-1473. https://doi.org/10.2147/OTT.S190001
Pongsapich, Warut, et al. "BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma." OncoTargets and therapy vol. 12 (2019): 1465-1473. doi: https://doi.org/10.2147/OTT.S190001
Pongsapich W, Chongkolwatana C, Poungvarin N, Amornpichetkul K, Piyawattayakorn N, Vejvisithsakul P, Maneeprasopchoke P. BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma. Onco Targets Ther. 2019 Feb 21;12:1465-1473. doi: 10.2147/OTT.S190001. eCollection 2019. PMID: 30863114; PMCID: PMC6391130.
Copy Download .nbib Format: NLM
Alzheimer's disease dementia as the diagnosis best supported by the cerebrospinal fluid biomarkers: difference in cut-off levels from thai experience.

International journal of Alzheimer's disease

Senanarong V, Siwasariyanon N, Washirutmangkur L, Poungvarin N, Ratanabunakit C, Aoonkaew N, Udomphanthurak S.
PMID: 22844634
Int J Alzheimers Dis. 2012;2012:212063. doi: 10.1155/2012/212063. Epub 2012 Jul 16.

Objectives. To determine how beta-amyloid 1-42 (Aβ 1-42), total tau (tTau), and phosphorylated tau (pTau) levels in CSF behave in a cohort of Thai patients from the Memory Clinic in Bangkok, Thailand. Methods. During 2009-2011, twenty eight subjects from...

Cite
Senanarong V, Siwasariyanon N, Washirutmangkur L, et al. Alzheimer's disease dementia as the diagnosis best supported by the cerebrospinal fluid biomarkers: difference in cut-off levels from thai experience. Int J Alzheimers Dis. 2012;2012:212063doi: 10.1155/2012/212063.
Senanarong, V., Siwasariyanon, N., Washirutmangkur, L., Poungvarin, N., Ratanabunakit, C., Aoonkaew, N., & Udomphanthurak, S. (2012). Alzheimer's disease dementia as the diagnosis best supported by the cerebrospinal fluid biomarkers: difference in cut-off levels from thai experience. International journal of Alzheimer's disease, 2012212063. https://doi.org/10.1155/2012/212063
Senanarong, V, et al. "Alzheimer's disease dementia as the diagnosis best supported by the cerebrospinal fluid biomarkers: difference in cut-off levels from thai experience." International journal of Alzheimer's disease vol. 2012 (2012): 212063. doi: https://doi.org/10.1155/2012/212063
Senanarong V, Siwasariyanon N, Washirutmangkur L, Poungvarin N, Ratanabunakit C, Aoonkaew N, Udomphanthurak S. Alzheimer's disease dementia as the diagnosis best supported by the cerebrospinal fluid biomarkers: difference in cut-off levels from thai experience. Int J Alzheimers Dis. 2012;2012:212063. doi: 10.1155/2012/212063. Epub 2012 Jul 16. PMID: 22844634; PMCID: PMC3403284.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries